Emerging treatment options for prostate cancer.

Mohammad AtiqElias B A ChandranFatima KarzaiRavi A MadanJeanny B Aragon-Ching

Published in: Expert review of anticancer therapy (2023)

Treatment landscape for metastatic castrate-resistant prostate cancer (mCRPC) has evolved beyond additional agents with ARPI and/or docetaxel, including other treatments with sipuleucel-T, radium, cabazitaxel, PARP inhibitors, and lutetium, which have specific indications and roles in sequencing. Novel therapies remain critically needed after progression from lutetium.

Keyphrases

prostate cancer
radical prostatectomy
single cell
squamous cell carcinoma
small cell lung cancer
dna damage
dna repair
radiation therapy
oxidative stress